Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #127 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Brooks Laboratories Limited (this stock) | 164 | 36.0 | 20.0% | -57.7% | — | 71 | 47 | 12 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 23 | 1 | -2 | ₹ |
| March 31, 2026 | 20 | 1 | 2 | ₹ |
| Dec. 31, 2025 | 17 | 0 | 5 | ₹ |
| Sept. 30, 2025 | 23 | 2 | 8 | ₹ |
| June 30, 2025 | 26 | 3 | 10 | ₹ |
| March 31, 2025 | 23 | 2 | -1 | ₹ |
| Dec. 31, 2024 | 21 | 1 | -2 | ₹ |
| Sept. 30, 2024 | 21 | 1 | -4 | ₹ |
| June 30, 2024 | 18 | -0 | -2 | ₹ |
| March 31, 2024 | 18 | 0 | -10 | ₹ |
| Dec. 31, 2023 | 22 | 1 | -4 | ₹ |
| Sept. 30, 2023 | 24 | 1 | -2 | ₹ |
| June 30, 2023 | 16 | -1 | -4 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 86 | 6 | 25 |
| March 31, 2025 | 83 | 3 | -10 |
| March 31, 2024 | 79 | 2 | -20 |
| March 31, 2023 | 63 | -36 | -32 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 9 | -3 | 0 | 4 | 6 |
| March 31, 2025 | 3 | -46 | 43 | 1 | 2 |
| March 31, 2024 | -10 | 0 | 10 | 0 | -10 |
| March 31, 2023 | -14 | 0 | 11 | 0 | -15 |
| March 31, 2022 | -37 | -25 | 64 | 28 | -65 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 148 | 123 | 93 | 6 | 1 | 37 | 22 | 7 | 13 | 11 |
| March 31, 2025 | 124 | 98 | 69 | 6 | 0 | 34 | 23 | 0 | 13 | 9 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
